Early vs. Delayed EVERolimus in de Novo HEART Transplant Recipients: Optimization of the Safety/Efficacy Profile (EVERHEART Study).

Trial Profile

Early vs. Delayed EVERolimus in de Novo HEART Transplant Recipients: Optimization of the Safety/Efficacy Profile (EVERHEART Study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Acronyms EVERHEART
  • Sponsors Novartis
  • Most Recent Events

    • 19 Sep 2017 Results published in the Transplantation.
    • 06 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Sep 2013 Interim results (n=100) presented at the 16th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top